We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Revamps Draft Guidance on Protocols for CMC Changes Following Approval
FDA Revamps Draft Guidance on Protocols for CMC Changes Following Approval
The FDA has a slate of new recommendations companies should follow when submitting a comparability protocol assessing changes to the chemistry, manufacturing or controls of a drug or biologic after the agency has approved its production process.